-
Friday, 19 March 2021 07:00SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy treatment SPVN06 have been accepted for the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, to be held virtually from 1-7 May.
Tuesday, 16 February 2021 07:00SparingVision Conference Participation in H1 2021SparingVision announces the conferences that its management team will be participating in in the first half of 2021.
Thursday, 04 February 2021 07:00Dr. Daniel C. Chung appointed as Chief Medical Officer of SparingVisionFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
Monday, 01 February 2021 07:00Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory BoardDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Thursday, 29 October 2020 08:00SparingVision Strengthens Management TeamWednesday, 21 October 2020 07:00SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive OfficerTuesday, 30 June 2020 08:00SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal DystrophiesTuesday, 03 December 2019 07:00SparingVision wins First Prize at EIT European Health Catapult competitionThursday, 25 July 2019 08:00SparingVision to Present at the Ophthalmology Innovation Summit (OIS) in Chicago on July 25th, 2019 during the American Society of Retinal Specialists (ASRS) meetingFriday, 05 July 2019 08:00SparingVision awarded at EIC Accelerator program (H2020 SME instrument Phase 2), securing funding of €2.5 millionThursday, 04 July 2019 08:00SparingVision sélectionnée au programme européen EIC Accelerator (H2020 SME instrument Phase 2) pour un financement de 2,5 millions d’eurosThursday, 25 April 2019 08:00SparingVision to present preclinical datas for Retinitis Pigmentosa’s treatment during Annual Congress of the Association for Research in Vision and Ophthalmology (ARVO)Tuesday, 26 February 2019 07:00Journée Internationale des Maladies RaresTuesday, 05 February 2019 07:00SparingVision récompensée par le « Mercure des Entrepreneurs HEC 2019 » dans la catégorie « Création d’Entreprise »Tuesday, 09 January 2018 07:00SparingVision sélectionnée pour une présentation publique au 10e Biotech Showcase™Monday, 08 January 2018 07:00SparingVision to Participate in the 10th Annual Biotech Showcase in San Francisco,Wednesday, 12 July 2017 08:001 For Release: July 12, 2017 Contact: Rhea Farberman, Foundation Fighting Blindness 410-423-0635 SparingVision Wins Grand Prize of 2017 i-Lab Contest for New, Innovative French Companies
Press releases